Advances of the influence of chronic renal failure on the pharmacokinetics

Abstract

Abstract: The chronic renal failure(CRF) is one of the common diseases in clinic. CRF affects the pharmacokinetics and pharmacodynamics of drug which either eliminate by renal or by nonrenal routes. The tests in vivo and in vitro demonstrated that renal impairment especially end-stage renal disease (ESRD) not only decreased the excretion by kidney, but also the alterations in the activities of and interplay between uptake and efflux transporters and metabolic enzymes significantly affected the PK disposition and resulting exposure of drugs cleared through nonrenal. CRF can directly inhibit the activity of various metabolic enzymes and transporters and in the other sides the CRF can down-regulate the mRNA and protein expression of metabolic enzymes and multiple intestinal and hepatic drug transporters. The reasons of those inhibition effects need more researches. The hemodialysis can partially offset or reverse this kinds of inhibition and dialysis clearance exist in the patient with ESRD.

Key words: Chronic renal failure, Pharmacokinetics, Advances

CLC Number:

R969

HUANG Yuan-yuan, ZHANG Hao, YI bing, FU Zhi-min, YANG Guo-ping. Advances of the influence of chronic renal failure on the pharmacokinetics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(6): 715-720.

References

[1] Coresh J, Selvin E, Stevens LA,et al. Prevalence of chronic kidney disease in the United States[J]. JAMA, 2007,298(17):2038-2047.
[2] Zhang L, Zhang P, Wang F, et al. Prevalence and factors associated with CKD: a population study from Beijing[J]. Am J Kidney Dis,2008, 51(3):373-384.
[3] Evans RS, Lloyd JF, Stoddard GJ, et al. Risk factors for adverse drug events: a 10-year analysis[J]. Ann Pharmacother, 2005, 39(7/8):1161-1168.
[4] Manley HJ, Cannella CA, Bailie GR,et al. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis[J]. Am J Kidney Dis,2005,46(4):669-680.
[5] AW Dreisbach. The influence of Chronic Renal Failure on drug metabolism and transport[J].Clin Pharmacol Ther, 2009,86(5):553-556.
[6] Leblond FA, Giroux L, Villeneuve JP, et al. Decreased in vivo metabolism of drugs in chronic renal failure[J]. Drug Metab Dispos, 2000,28(11):1317-1320.
[7] Leblond FA, Petrucci M, Dube P, et al. Downregulation of intestinal cytochrome P450 in chronic renal failure[J]. J Am Soc Nephrol, 2002,13(6):1579-1585.
[8] Dani M, Boisvert C, Michaud J, et al.Downregulation of liver drug metabolizing enzymes in a murine model of chronic renal failure[J]. J Am J Physiol Renal Physiol, 2010,38(3):357-360.
[9] 李晓宇,刘皋林.CYP 450酶特性及其应用研究进展[J].中国临床药理学与治疗学,2008,13(8):942-946.
[10] Karara AH, Frye RF, Hayes PE, et al. Pharmacokinetics of abecarnil in patients with renal insufficiency[J]. Clin Pharmacol Ther, 1996,59(5):520-528.
[11] Turpeinen M, Koivuviita N, Tolonen A, et al. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites [J]. Br J Clin Pharmacol, 2007,64(2):165-173.
[12] Dreisbach AW, Japa S, Gebrekal AB, et al. Cytochrome P4502C9 activity in end-stage renal disease[J]. Clin Pharmacol Ther, 2003,73(5):475-477.
[13] Glue P, Sulowicz W, Colucci R, et al. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction[J]. Br J Clin Pharmacol, 1997,44(1):91-93.
[14] Czock D, Keller F, Heringa M, et al. Raloxifene pharmacokinetics in males with normal and impaired renal function[J]. Br J Clin Pharmacol, 2005,59(4):479-482.
[15] Vormfelde SV, Muck W, Freudenthaler SM, et al. Pharmacokinetics of crivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance[J]. J Clin Pharmacol, 1999,39(2):147-154.
[16] Aronoff G, Brier M, Mayer ML, et al. Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function [J]. J Clin Pharmacol, 1991,31(1):38-44.
[17] De Martin S, Orlando R, Bertoli M, et al. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis[J]. Clin Pharmacol Ther, 2006,80(6):597-606.
[18] Kim YG, Shin JG, Shin SG, et al. Decreased acetylation of isoniazid in chronic renal failure[J]. Clin Pharmacol Ther, 1993,54(6):612-620.
[19] Nolin TD, Frye RF, Le P, et al. ESRD impairs nonrenal clearance of fexofenadine but not midazolam[J]. J Am Soc Nephrol, 2009,20(10):2269-2276.
[20] Simard E, Naud J, Michaud J,et al. Downregulation of hepatic acetylation of drugs in chronic renal failure[J]. J Am Soc Nephrol, 2008,19(7):1352-1359.
[21] Yu C, Ritter JK, Krieg RJ,et al.Effect of chronic renal insufficiency on hepatic and renal udp-glucuronyltransferases in rats[J]. Drug Metab Dispos,2006,34(4):621-627.
[22] Veau C, Leroy C, Banide H, et al. Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion[J]. Nephrol Dial Transplant, 2001,16(8):1607-1614.
[23] Naud J, Michaud J, Boisvert C,et al. Down-regulation of intestinal drug transporters in chronic renal failure in rats[J]. J Pharmacol Exp Ther, 2007,320(3):978-985.
[24] 王磊,李宁,陈西敬.转运体在药物排泄中的作用及在新药研发中的意义[J].中国临床药理学与治疗学,2009,14(4):448-454.
[25] Naud J, Michaud J, Leblond FA, et al. Effects of chronic renal failure on liver drug transporters[J]. Drug Metab Dispos, 2008,36(1):124-128.
[26] Nolin TD, Appiah K, Kendrick SA, et al. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity[J]. J Am Soc Nephrol,2006,17(9):2363-2367.
[27] Michaud J, Nolin TD, Naud J, et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression[J]. J Pharmacol Sci, 2008,108(2):157-163.
[28] Dowling TC, Briglia AE, Fink JC, et al. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease[J]. Clin Pharmacol Ther, 2003,73(5):427-434.
[29] Sun H, Huang Y, Frassetto L, et al. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin[J]. Drug Metab Dispos, 2004,32(11):1239-1246.
[30] Michaud J, Naud J, Chouinard J, et al. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure[J]. J Am Soc Nephrol, 2006,17(11):3041-3048.